Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Pain Physicians (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 21, 2008
Later Administration of Alvimopan (Entereg, Adolor) Accelerates GI Recovery
Analysis of: Study Published In Archives Of Surgery Demonstrated Benefit Of Entereg (Alvimopan) In Postoperative Ileus | pharmalive.com
Author: GLG Expert Contributor
Alvimopan given 30 to 90 minutes before surgery showed similar benefit as when given more than 2 hours pre-operatively.  Since patients often don’t arrive at the hospital 2 hours before surgery, it would certainly be more convenient to administer the drug closer to the time of surgery.
Daniel WynnNovember 17, 2008
"Tamper-Proof" -- A Significant Gain to Whom??
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
August 6, 2008
POISE: don't let it change your practice
Analysis of: Higher Risk of Death and Stroke in Patients Given Beta Blockers After Non-Cardiac Surgery (POISE Trial) | pharmalive.com
Author: GLG Expert Contributor
1. 10% of the data was rejected because the data was "fraudulent" - ie: research centers received payment, but there was not actually a patient associated with the data points. 2. No oversight was conducted of the research locations.  A majority of research centers were in various 3rd world countries. ...
July 28, 2008
Patients will continue to decrease the use of these agents for reasons that I can speculate are largely related to lack of perceived efficacy the fear of the unknown
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor
This should not deter the practicing physician to prescribe these agents osteoporosis will reach epidemic proportions and if we can reduce fractures by 50% the savings within the healthcare system will be enormous that's not to say that individuals albeit rare may have a propensity to develop fractures...
Jason CampagnaJuly 2, 2008
The Pleitropic Effects of Volatile Anesthetics: Pain and Inhaled Agents?
Analysis of: Why anaesthetics can make the pain worse | www.newscientist.com
Author: Jason Campagna, Director of Clinical Quality and Analytics, Cottage Health System
There are well over 70 Million general anesthetics performed in the US each year, and the majority of these utilize one of four generally used inhaled anesthetic agents (Sevoflurane, Desflurane, Isoflurane and Halothane). How these drugs act to produce "unconsciousness" is largely unknown, but as the...
July 2, 2008
Anesthetic factors that modulate postoperative pain
Analysis of: Why anaesthetics can make the pain worse | www.newscientist.com
Author: GLG Expert Contributor
1/ Genetic factors. Data indicate that genetic factors modulate the anesthetic requirement to control pain duirng and after surgery 2/ Gender sensitivity to anesthetics 3/ Anesthesia or lack of it  may lead to increase postoperative pain 4/ lack of proper perioperative monitoring of pain 5/ lack...
Daniel WynnJune 5, 2008
Novartis and Multiple Sclerosis: A Major Commitment
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...
Daniel WynnJune 2, 2008
Abbott's ABT-089 --Much More than a Treatment for ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
May 15, 2008
Sustained-release Hydrocodone - so what?
Analysis of: New Abbott Study of Investigational Vicodin CR(TM) Meets Primary Efficacy Endpoints in Phase III Trial | www.prnewswire.com
Author: GLG Expert Contributor
Abbott is developing a sustained-release formulation of hydrocodone.
May 12, 2008
Sustained-release opioids
Analysis of: New Abbott Study of Investigational Vicodin CR(TM) Meets Primary Efficacy Endpoints in Phase III Trial | www.prnewswire.com
Author: GLG Expert Contributor
The availability of any existing opioid molecule as a sustained-release preparation, eg Vicodin CR, is an advance in pain management.  That being said, however, there is little evidence that the risk of abuse or addiction is less with SR opioids.  In fact, the (usually) higher doses is SR...

Page : 1 2 3 4 5 6 Next1 to 10 of 52

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203